US FDA advisers recommend against Otsuka's PTSD combination treatment
The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft, chemically known as sertraline, for treating the condition. Its decision is in line with the FDA staff reviewers' assessment on Wednesday.
Otsuka's application was based on the data from one mid-stage and two late-stage studies testing the combination treatment compared to sertraline plus placebo. It had failed to meet the main goal of significantly reducing severity of PTSD symptoms in one of the late-stage studies compared to sertraline and placebo.
PTSD, a disorder caused by very stressful events, affects about 4% of U.S. adults and is commonly associated with war veterans. But natural disasters, abuse or other trauma may also trigger the condition in civilians.
"We simply cannot negate one negative study and say we are going to approve based on two other positive studies," said panelist Pamela Shaw, biostatistician at Kaiser Permanente.
Otsuka did not immediately respond to a Reuters request for comment.
The advisers discussed possible side-effects such as weight gain and movement disorders associated with long-term use of antipsychotics, but noted that the combination may be a better treatment option for patients who respond poorly to sertraline alone.
"The big question for me is knowing that antipsychotics can cause real problems, especially with long-term use, and the modest benefit that the combination treatment potentially can offer," said panelist Walter Dunn, assistant clinical professor of psychiatry at university of California Los Angeles.
The FDA, originally set to decide on the company's application by February 8, delayed its decision to seek the advisory panel's input. The agency has not set a new action date for the drug.
The health regulator typically follows the advice of its expert advisers, but is not required to do so.
If approved, the combination drug would be the first PTSD treatment to gain U.S. nod in more than two decades after Zoloft and GSK's (GSK.L), opens new tab Paxil.
Brexpiprazole, branded as Rexulti, is approved in the U.S. to treat agitation in patients with Alzheimer's disease as well as for adults with major depressive disorder and schizophrenia.
The drug is being co-developed by Otsuka and Danish drugmaker Lundbeck (HLUNa.CO), opens new tab.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
an hour ago
- Times
When the doctors gave up, ChatGPT found a cure
Move over, Dr Google. The era of Dr GPT has arrived. A friend of mine has for some time been suffering from an escalating histamine intolerance that was actually becoming life-limiting. Histamines, for those who have never had to find out, are chemicals produced by our immune systems or by bacteria that can trigger inflammation and which are present in a dizzying array of food: aged or cured meat, tomatoes, strawberries, many kinds of fish, dairy, aubergine, red wine and so on. Histamine intolerance often involves severe hay fever too, thrown in just for fun. For my friend, dietary changes and various doctors were failing to contain the problem. So, almost out of ideas, my friend's partner took to ChatGPT for troubleshooting. He put in the condition and the symptoms. And within a few minutes, he had some ideas to try: pea sprout powder and nettle tea. Better than nothing, which is what the official medical routes had to offer, and both are known to have anti-histamine properties.
Daily Mail
an hour ago
- Daily Mail
EXCLUSIVE The truth about 'suicide headaches' and the bizarre treatments I tried in search of a cure
Tom Zeller Jr has done just about anything to get rid of his headaches. He's chugged 60 glasses of water in a day, inhaled oxygen straight from the tank and even tripped on magic mushrooms on top of the western Montana mountains. The 56–year–old science journalist was diagnosed about three decades ago with cluster headaches, debilitating headaches that strike randomly and drag out for weeks or months at a time. While it could be years between attacks, they return as fast as a lightning strike, with Zeller likening them to resting your hand on a hot burner and not being able to take it off. Zeller told 'They're excruciatingly painful. The tend to come on really, really quickly, within a matter of seconds. You don't usually have a warning and they will knock you down to the floor until they're over.' Zeller, who lives in Montana, spent much of his adult life suffering attacks up to four times a day for months at a time until they suddenly disappeared. His clusters have slowed in recent years, but like the 1 in 1,000 Americans with the disorder, Zeller waits for the next attack with limited tools at his disposal. In his newly released book, The Headache: The Science of a Most Confounding Affliction – and a Search for Relief, Zeller detailed his decades–long search for cluster headache relief, along with the wackiest things he's tried to quell the pain. 'I never wanted to write this book, to be honest. I did not want people to know I had headaches. It's just terrible to be seen in this way,' Zeller told 'But I also felt like if you're going to write a book, they say, "Write about what you know." I realized that I know headaches.' Cluster headaches are extremely painful and strike quickly in frequent attacks, or 'clusters,' lasting weeks or months at a time, earning the grim nickname 'suicide headaches.' The disorder usually causes sharp and stabbing pain in or around the eye, restlessness, tears and eye redness, forehead sweating, swelling around the eye and eyelid drooping. While a close relative of migraines, they're far less common. About 0.1 percent of Americans have had a cluster headache attack at some point in their lives, while 15 percent – most of whom are women – have migraines. For Zeller, the attacks drove a wedge in his journalism career, often forcing him to 'retreat from opportunities in the newsroom.' 'It's not easy. The book talks about how any sort of headache disorder is kind of a drag on the momentum of your life. They're always slowing you down,' he said. 'When I wasn't having the headaches, I felt like I was pretty bold and pretty accomplished as a journalist. But when the headaches would come on, I would sort of disappear and I would work from home a lot. 'There's a lot of stigma attached to headaches in a weird way. I tried very hard to make sure that no one knew that I had these headaches. You start to hide and that meant hiding from opportunities at work too.' Throughout the book, Zeller detailed a laundry list of unorthodox treatments he tried or researched. 'I was being ground down by the relentless injections, self–administered into an abdomen bruised and pockmarked by previous jabs, and overuse of the medication was likely driving an endless cycle of rebound attacks,' he wrote in his book. 'Given this unappealing tableau, why not shrooms?' Psilocybin, the active compound in magic mushrooms, has been shown to alter how the brain processes and perceives pain signals and is thought to reduce inflammation. He's also tried inhaling capsaicin, an extract in chili peppers that gives them their signature heat. Some research suggests it helps desensitize nerve fibers in the nasal passages that transmit cluster headache pain to the brain. Zeller also rented oxygen tanks from a welding supplier as a 'really fast way to abort a cluster headache attack.' 'I also remember a forum saying that if you just tried to chug like 60 glasses of water a day, or some absurd amount, it would cure your headaches. I was willing to try, but all I did was visit the toilet a lot with headaches,' he recalled. Zeller said many patients with cluster headaches have to rely on bizarre hacks because of the lack of medications geared specifically toward their condition. 'The thing that surprised me most, and what probably prompted the book, was that so little research was out there on primary headache disorders,' Zeller explained. Patients are often prescribed beta blockers, antipsychotics, antidepressants and other drugs manufactured for other illnesses, as they can treat headaches in some people. Recently, the advent of CGRP drugs has changed the picture. Approved by the FDA in 2018, these preventative drugs block or reduce the effects of CGRP, which causes migraine and cluster headache pain. 'A lot of times you'll find a drug or remedy that does kind of work, but the body adapts. We're very plastic, and over time, those things start to wane,' Zeller said. Zeller uses the CGRP medication Emgality, the only FDA approved medication specifically designed for cluster headaches and migraines. The cluster headache dose of Emgality is significantly higher than the migraine dose – 300 milligrams compared to 120 milligrams – and both versions are given through a subcutaneous injection just under the skin. 'Cluster headaches are their own unique animal, so once the headaches start happening, it does seem to be pretty hard to stop,' Zeller revealed. 'But I think three times in I'm sort of convinced that the CGRP blockers work for me to stop a bout from happening.' Like migraines, cluster headaches often become less frequent and severe with age, which some research suggests could be due to hormonal fluctuations and altered blood vessel function in the brain. Zeller's clusters in recent years have slowed and can now fall years apart, but he's far from being in remission. 'I don't think I, or anyone really, is out of the woods yet,' he said. For now, Zeller said he hopes his new book will help improve cluster headache awareness and provide a sense of community for readers with the condition. In his research, he spoke with several cluster headache and migraine patients who at first were 'guarded' and wary of speaking about their experience over fears of it being trivialized. But throughout the interviews, they became excited because they had 'this pent–up desire to just unload about it.' 'I hope they feel seen by the book,' Zeller said. 'Someone out there is paying attention and you can take heart in that, and if you're able to buy time between painful bouts, I hope that you know the book will be affirming in that you know you're not alone.' The Headache: The Science of a Most Confounding Affliction – and a Search for Relief is available on Amazon, Barnes & Noble, Target and others.
The Independent
2 hours ago
- The Independent
Dogs prefer certain TV shows depending on their personality type, researchers find
Dogs prefer certain TV shows depending on whether their personality is nervous or excitable, researchers in the US have revealed. Auburn University experts in Alabama recruited 453 dogs, aged from four months to 16 years old, and their owners to record their responses to different TV shows. 'The survey investigated trends in the dogs' TV viewing habits, including whether the owner tried to teach the dog to watch TV, the average number of hours per week the owner's TV is switched on, and the average number of seconds the dog pays attention to the TV,' researchers told The Times. 'Dogs who were more excitable were more likely to exhibit behaviours suggesting an expectation that the television stimulus exists in the 3D environment,' said the researchers, whose study was published in Scientific Reports. 'Furthermore, dogs who displayed more fearful tendencies were more likely to respond to the non-animal stimuli, for example, car [or] doorbell.' Last year, scientists revealed the trick to getting your pet dog to understand what you are saying. The research, published in October, claimed people should try speaking a little bit slower. It concludes that dogs' comprehension of human speech relies on a slower tempo. Despite not being able to produce human sounds, man's best friend is capable of responding to human speech. When people talk slowly, it matches the receptive abilities of animals, allowing dogs to better understand commands, researchers say. Writing in the Plos Biology journal, the authors said: 'Comparative exploration of neural and behavioural responses to speech reveals that comprehension in dogs relies on a slower speech rhythm tracking than humans', even though dogs are equally sensitive to speech content and prosody.' They hypothesise that people may adjust their speech rate 'as means to improve communication efficacy'. Eloise Deaux, of the University of Geneva in Switzerland, and colleagues analysed the vocal sounds of 30 dogs, and the sounds of 27 humans across five languages speaking to other people, and 22 humans across those languages speaking to dogs.
